ENOVNYSEOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31
Enovis CORP
Financials through Q2 FY2026, quarter ended Jul 3, 2026Last filing: 10-Q on Aug 6, 2026
$19.87+0.28 (+1.43%)
Close on Oct 19, 2026
- Market cap
- $1.14B
- P/E (TTM)
- –
- Dividend yield
- –
Enovis CORP revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reconstructive | $294.53M | $317.13M | $292.88M | $257.97M | $273.98M | $286.25M | $274.03M | $230.98M | $247.41M | $257.25M | $172.75M | $147.24M | 50.5% | +7.5% |
| Prevention & Recovery | $288.25M | $272.02M | – | – | $290.57M | $272.58M | – | – | – | – | – | – | 49.5% | -0.8% |
| Prevention & Recovery: | – | – | $282.88M | $290.94M | $290.57M | $272.58M | $286.95M | $274.24M | $277.75M | $259.01M | $282.27M | $270.29M | – | – |
By product or service
By region
From the segment and revenue-disaggregation notes of Enovis's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.